Telix Shares Fall After Launch of Radiochemistry Platform, Belgium University Agreement

MT Newswires Live

Jun 23, 2025

Shares of Telix Pharmaceuticals (ASX:TLX) fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen (PSMA) in prostate cancer patients, according to a June 20 statement by the company.

The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.

The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.

The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545450235"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545450235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545450235?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545450235","market":"nz","top_or_hot":-1,"title":"Telix Shares Fall After Launch of Radiochemistry Platform, Belgium University Agreement","media":"MT Newswires Live","content":"<html><body><p> Shares of <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen (PSMA) in prostate cancer patients, according to a June 20 statement by the company.</p><p>The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.</p><p>The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.</p><p>The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix Shares Fall After Launch of Radiochemistry Platform, Belgium University Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix Shares Fall After Launch of Radiochemistry Platform, Belgium University Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-23 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shares of <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen (PSMA) in prostate cancer patients, according to a June 20 statement by the company.</p><p>The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.</p><p>The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.</p><p>The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545450235","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545450235","pubTimestamp":1750644130,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shares of Telix Pharmaceuticals  fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen  in prostate cancer patients, according to a June 20 statement by the company.The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"比利时大学协议推出放射化学平台后Telix股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"Shares of Telix Pharmaceuticals (ASX:TLX) fell almost 4% in Monday morning trade after the company launched AlFluor, a radiochemistry platform, to enable flexible labelling of prostate-specific membrane antigen (PSMA) in prostate cancer patients, according to a June 20 statement by the company.The platform supports both centralized cyclotron manufacturing and distributed kit production, the company said.The company also entered into a strategic agreement with University Hospital Ghent and Ghent University for access to a PSMA-targeting agent, per the statement.The deal includes a comprehensive chemistry, manufacturing, and controls package and exclusive rights to clinical data, including the data of a phase 3 trial in 96 prostate cancer patients, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}